UCB Articles
Pfizer And UCB Get FDA OK For Zyrtec In Kids
4 June 1998
Stock Commentary Europe
7 May 1998
Stock Commentary Europe
23 April 1998
Stock Commentary Europe
16 April 1998
Collaborations And Licensing News In Brief
26 March 1998
Stock Commentary Europe
19 February 1998
Profits At Belgium's UCB Leap 33%
13 February 1998
Top Firms Maintaining Strong Sales & Profits
13 January 1998
"Excellent" 1997 Profits For UCB?
8 January 1998
Stock Commentary Europe
4 December 1997
European and London Stock Comment
7 August 1997
UCB Tries To Quells Takeover Speculation
5 August 1997
European And London Stock Comment
19 June 1997
Favorable Prospects In 1997 At UCB
18 June 1997
Favorable Growth Expected At UCB
12 June 1997
UCB In Malaysia
30 May 1997
"Excellent" Year For UCB In 1996
21 April 1997
UCB Sees Improved Profits In 1996
10 February 1997
EUROPEAN AND LONDON STOCK COMMENT
27 January 1997
Acquisitions And Mergers Continue, Led By Novartis
6 January 1997
UCB Expects Good Results From 1996
6 January 1997
EUROPEAN AND LONDON STOCK COMMENT
25 November 1996
UCB Sells Fine Chemicals Subsidiary
14 October 1996
European And London Stock Comment
12 August 1996
Zyrtec Drives Profits At UCB
5 August 1996
UCB Pharma's Lortab Approval
22 July 1996
Favorable Prospects For UCB In 1996
1 July 1996
UCB Opens New Facility
3 June 1996
UCB In The Philippines
25 March 1996
Improvement In 1995 For UCB
11 March 1996
Thai PPA Directors
5 February 1996
EUROPEAN STOCK COMMENT
5 February 1996
Penederm /UCB agreement for antifungal KP363
29 January 1996
UCB Optimistic On 1995; Zyrtec Launch
15 January 1996
Pfizer: Zyrtec news
18 December 1995
UCB In Japan
27 November 1995
USA Lags Foreign Approvals, PhRMA Demonstrates
16 October 1995
UCB Ord Profit Up 74%
7 August 1995
EUROPEAN STOCK COMMENT
7 August 1995
International Pharma Expansion AT UCB
3 July 1995
EUROPEAN STOCK COMMENT
26 June 1995
UK POM-To-P Switches At End-June
19 June 1995
Sharp Increases In Profits In 1994 At UCB
17 April 1995
UCB Results
27 February 1995
FDA Says UCB/Pfizer's Zyrtec Is Approvable
27 February 1995
UCB Sales
2 January 1995
New Anticancer Agents: Phase II Trial Results
12 December 1994
UK Code Of Conduct Quarterly Review
17 October 1994
UCB Acquisition
17 October 1994
Ethyl Corp To Sell Whitby Drug Division
19 September 1994
UCB's 1994 1st Half
8 August 1994
CHOSEIDO TERMINATES UCB AGREEMENT
6 June 1994
HOLISTIC MARKETING
6 June 1994
EUROPEAN STOCK COMMENT
30 May 1994
UCB RESULTS
16 May 1994
EUROPEAN STOCK COMMENT
4 April 1994
UCB LAUNCHES OTC ZIRTEK
14 March 1994
UCB INTRODUCES DRINKABLE FORMUALTION OF ZIRTEK
21 February 1994
UCB SPANISH UNIT
15 November 1993
HOECHST-ROUSSEL TO FIGHT COGNEX PATENT
11 October 1993
BELGIUM'S UCB POSTS LOWER SALES AND PRETAX PROFITS
20 September 1993
MERCK AG SALES SEES GOOD GROWTH
20 September 1993
EUROPEAN STOCK COMMENT
19 July 1993
UCB PROFITS UP 17%
21 June 1993
PRE-LAUNCH TEAM ROLES AND RESPONSIBILITIES
14 June 1993
EARNINGS GROWTH EXPANSION SEEN FOR UCB
31 May 1993
UCB ACQUIRES KOREAN FACILITY
10 May 1993
1992 "A GOOD YEAR" SAYS UCB
3 May 1993
UCB SELLS VEL DISTRIBUTION
29 March 1993
UCB'S NOOTROPIL APPROVED IN UK
22 February 1993
SIBA TO DEVELOP ANTI-EPILEPSY DRUG
25 January 1993
UCB EXPECTS GOOD 1992 PROFITS
18 January 1993
GROWTH FOR EURO PEPTIDES MARKET
7 December 1992
NEW FACTORY FOR UCB
7 September 1992
good pharma results for UCB: '91
6 July 1992
UCB signs deal
15 June 1992
UCB EXPANDS ACTIVITIES IN POLAND
15 June 1992
STOCK MARKET COMMENTARY: EUROPE
27 April 1992
SLIGHT RISE IN UCB PRETAX PROFITS
20 April 1992
ALZHEIMER'S DISEASE: A GROWING BURDEN
20 January 1992
FEWER ACQUISITIONS AND MERGERS IN 1991
6 January 1992
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
